Jake Simson
Director/Board Member bij TYRA BIOSCIENCES, INC.
Vermogen: - $ op 31-03-2024
Profiel
Jake Simson is currently serving as the Director at Aavantibio, Inc., Independent Director at Janux Therapeutics, Inc., Director at Cedilla Therapeutics, Inc., Independent Director at Tyra Biosciences, Inc., Director at DICE Molecules SV, Inc., and Non-Executive Director at Xenikos BV.
He is also a Partner at RA Capital Management LP (Private Equity) and RA Capital Management LP.
Previously, he held the position of Independent Director at DICE Therapeutics, Inc. from 2020 to 2023.
Dr. Simson obtained a doctorate degree from The Johns Hopkins University in 2013 and an undergraduate degree from the Massachusetts Institute of Technology in 2008.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC.
-.--% | 04-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
TYRA BIOSCIENCE, INC
-.--% | 26-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Jake Simson
| Bedrijven | Functie | Begin |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Director/Board Member | 01-01-2020 |
| JANUX THERAPEUTICS, INC. | Director/Board Member | 01-03-2021 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Analyst-Equity | - |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01-12-2017 |
DICE Molecules SV, Inc.
 DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | Director/Board Member | 08-01-2021 |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Director/Board Member | - |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Director/Board Member | - |
Cedilla Therapeutics, Inc.
 Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Eerdere bekende functies van Jake Simson
| Bedrijven | Functie | Einde |
|---|---|---|
| DICE THER | Director/Board Member | 09-08-2023 |
Opleiding van Jake Simson
| Massachusetts Institute of Technology | Undergraduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| TYRA BIOSCIENCES, INC. | Health Technology |
| JANUX THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Finance |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
DICE Therapeutics, Inc.
 DICE Therapeutics, Inc. BiotechnologyHealth Technology DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | Finance |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
